Overview

Mood and Cognitive Effects of Psilocybin in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is seeking to find the optimal microdose or low dose of psilocybin (magic mushrooms) that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic effects.
Phase:
Early Phase 1
Details
Lead Sponsor:
Optimi Health Corporation
Collaborator:
University of Calgary
Treatments:
Psilocybin